Deuterated colexitinib (decavatinib) medical insurance reimbursement policy and precautions for self-pay patients

Deucravacitinib (Deucravacitinib) is a new generation of selective TYK2 inhibitors, mainly used to treat autoimmune diseases such as moderate to severe plaque psoriasis. The drug selectively inhibits the TYK2 pathway, thereby blocking key inflammatory signals such as IL-12, IL-23 and type I interferon, thereby controlling skin damage and reducing inflammatory reactions. At present, deuterated coxitinib has been officially launched in China and has been included in the national medical insurance directory, which brings a more accessible treatment option to the majority of psoriasis patients.

According to the latest market price information, the price of the domestic version of deuterated colexitinib6mg*7 tablets is around more than one thousand yuan, and it can be reimbursed through medical insurance. Medical insurance reimbursement ratios vary slightly in different regions, but after overall reimbursement, patients' out-of-pocket expenses have dropped significantly, reducing the financial burden caused by long-term medication. Doctors usually develop individualized plans based on the condition and guide patients to purchase regular drugs at designated hospitals or pharmacies designated by the medical insurance to ensure that the sources of drugs are reliable and the quality is controllable.

At the same time, prices vary widely in foreign markets. The price of the original American version of deuterated colexitinib6mg*30 tablets is as high as about 50,000 yuan, which is much higher than the domestic price. In places such as Laos and Bangladesh, there are already legally marketed generic versions of deuterated colexitinib, whose pharmaceutical ingredients are consistent with the original drug. The price of 6mg*30 tablets is around four to five hundred yuan. For patients who are not fully covered by medical insurance or require long-term medication, generic drugs have become a relatively economical alternative. However, patients should purchase through formal international drug channels and avoid purchasing drugs from unknown or uncertified sources.

Overall, the medical insurance coverage of colexitinib has greatly improved its clinical accessibility, but self-paying patients should still pay attention to the authenticity and legal channels of the drug. It is recommended that patients choose the appropriate version under the guidance of a doctor, strictly follow the doctor's instructions and take medication regularly, and have regular follow-up visits to monitor liver function, immune indicators, etc. For patients who need to purchase drugs across borders, they must keep prescriptions, invoices and drug inspection certificates to ensure that the medication process is safe, legal and traceable, so as to obtain curative effects while minimizing economic and safety risks.

Reference materials:https://www.drugs.com/